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Introduction: Activation of endogenous stem cell mobilization can contribute to myocardial regeneration after
ischemic injury. This study aimed to evaluate the possible role of Avemar or Echinacea extracts in inducing
mobilization and homing of CD34+ stem cells in relation to the inflammatory and hematopoietic cytokines in rats
suffering from acute myocardial infarction (AMI).
Methods: AMI was developed by two consecutive subcutaneous injections of isoprenaline (85 mg/kg). AMI rats
were either post-treated or pre- and post-treated daily with oral doses of Avemar (121 mg/kg) or Echinacea
(130 mg/kg). In whole blood, the number of CD34+ cells was measured by flow cytometry and their homing to the
myocardium was immunohistochemically assessed. Serum creatine kinase, vascular endothelial growth factor,
interleukin-8 and granulocyte macrophage colony stimulating factor were determined on days 1, 7 and 14 after
AMI. Sections of the myocardium were histopathologically assessed.
Results: Rats pre- and post-treated with Avemar or Echinacea exhibited substantial increases in the number of
circulating CD34+ cells, peaking on the first day after AMI to approximately 13-fold and 15-fold, respectively, with a
decline in their level on day 7 followed by a significant increase on day 14 compared to their corresponding AMI
levels. Only post-treatment with Echinacea caused a time-dependent increase in circulating CD34+ cells on days 7
and 14. Such increases in circulating CD34+ cells were accompanied by increased homing to myocardial tissue 14
days after AMI. Interestingly, pre- and post-treatment with Avemar or Echinacea substantially increased serum
creatine kinase on day 1, normalized its activity on day 7 and, on continued treatment, only Echinacea markedly
increased its activity on day 14 compared to the corresponding AMI values. Moreover, both treatments modified
differently the elevated serum vascular endothelial growth factor and the lowered granulocyte macrophage colony
stimulating factor levels of the AMI group but did not affect the level of interleukin-8. These results were supported
histopathologically by reduced inflammatory reactions and enhanced neovascularization.
Conclusion: Avemar and Echinacea extracts can effectively induce mobilization and homing of CD34+ stem cells to
the myocardial tissue and thus may help in stem cell-based regeneration of the infarcted myocardium.Introduction
Myocardial infarction (MI) is one of the major causes of
cardiovascular morbidity and mortality. MI results in
loss of cardiomyocytes, scar formation, ventricular re-
modeling and eventually heart failure. Although current
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dead myocardium and/or prevent deterioration of car-
diac function [1]. In last decade, stem cell (SC) therapy
has emerged as a potential new strategy for incurable
and life-threating MI. The ultimate goals of SC therapy
are myocardial regeneration and neovascularization lead-
ing to clinical improvement without severe adverse effects.
Mechanisms involved in the endogenous SC-associated
myocardial regeneration include the mobilization of SCs
from the bone marrow (BM) and other putative “niches”
(such as skeletal and cardiac muscles), cytokine-guidedarticle is distributed under the terms of the Creative Commons Attribution 4.0
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area, and finally the transdifferentiation into functional
cardiomyocytes. These tissue-committed SCs circulate in
peripheral blood at low number and can be mobilized by
ischemia-related inflammatory and hematopoietic cyto-
kines, such as granulocyte colony-stimulating factor (G-
CSF), granulocyte macrophage colony-stimulating factor
(GM-CSF), interleukin (IL)-8, vascular endothelial growth
factor (VEGF), and stromal cell-derived factor-1 (SDF-1)
[2–5]. The levels of these cytokines were found to be sig-
nificantly higher in patients with acute myocardial infarc-
tion (AMI) and were correlated positively with the
number of circulating CD34+ SCs [4]. However, such en-
dogenous responses unfortunately do not offer a sufficient
regenerative solution of damaged myocardium. Therefore,
the need for SC therapy is a must. Basically, the efficacy of
SC therapy in regenerative medicine depends on sufficient
recruitment of available cells (either exogenously adminis-
tered populations or endogenously mobilized residents) to
the target tissue.
Although SC transplantation is the most common
means to replenish impoverished SC pools, their applica-
tions are restricted by the limited availability of SC
sources, the excessive cost and the anticipated difficul-
ties of clinical translation and regulatory approval. Thus,
regenerative therapy should not be limited to this ap-
proach but should instead seek for a strategy that re-
trieves the initial healing capacity of a tissue [2]. In this
regard, pharmacological activation of endogenous SCs
already present in a patient’s body from either the blood
or a tissue-specific niche and their homing into the in-
jury sites is a promising approach for therapeutic suc-
cess. This technique has the potential to provide new
therapeutic options for in situ tissue regeneration. Such
options would be less costly and complex than ap-
proaches requiring ex vivo cell manipulation [2, 3]. In
this context, using medicinal plant products for activa-
tion of endogenous SCs represents an emerging field of
regenerative medicine in health and disease.
In the current study, two natural products, namely
Avemar and Echinacea, were selected to investigate their
possible role in supporting SC biology. Avemar is a
product of industrial fermentation of wheat germ with a
standardized content of benzoquinone and plant flavo-
noids that has been reported as safe and effective anti-
cancer and immunomodulatory adjuvant therapy for
human cancer [6]. Avemar also has a potential role to at-
tenuate the cardiovascular symptoms induced by hyper-
tension or diabetes. The proposed mechanisms were
attributed to its actions in inhibition of cyclooxygenase
isoforms and upregulation of endogenous antioxidants
[7]. On the other side, Echinacea purpurea is one of the
Echinacea species which has been widely used for its
anti-inflammatory and antioxidant activity in addition toa profound immunostimulatory action on a number of
human immune cells, such as macrophages and periph-
eral blood mononuclear cells [8]. Clinical trials con-
firmed the efficiency of Echinacea purpurea extracts in
inflammatory diseases, including those of an infectious
nature [9]. Echinacea has been shown to improve the re-
generation process of damaged tissues where it can in-
tensify the immunological angiogenesis which could be
of high benefit in wound healing and in future cardi-
ology as a preventive for MI [10]. Thus, we hypothesized
that treatment with Avemar and Echinacea may help in
regeneration of damaged myocardium via stimulating
SCs. In this regard, the effect of these natural products
on activation of endogenous SCs cannot be separated
from their already known antioxidant, anti-inflammatory
and immunomodulatory activities, as all of these activ-
ities are speculated to synergistically drive tissue repair
and regeneration.
Thus, this study was directed for the first time to in-
vestigate the possible effect of Avemar or Echinacea on
enhancing CD34+ SC mobilization, and homing in rela-
tion to inflammatory and hematopoietic cytokines such
as VEGF, IL-8 and GM-CSF in a rat model of AMI.
Methods
Animals
Male Wistar rats, weighing 170 ± 20 g, were obtained
from animal facility of the Faculty of Pharmacy, Cairo
University. The animals were housed in plastic cages
under controlled temperature (25 ± 2 °C) and a constant
12-h light/12-h dark cycle throughout the experiment. A
standard rat chow diet and water were allowed ad libi-
tum. The investigation complies with the Guide for Care
and Use of laboratory Animals published by the US
National Institutes of Health (NIH publication No. 85–23,
revised 1996) and was approved by the Ethics Committee
for Animal Experimentation at the Faculty of Pharmacy,
Cairo University.
Materials
Isoprenaline was purchased from Sigma-Aldrich Chemical
Co. (USA) and freshly prepared before injection in normal
saline at a concentration of 100 mg/ml. Avemar (standard-
ized fermented wheat germ extract) was purchased
from American Biosciences Inc. (USA) and was freshly
prepared in cold distilled water at a concentration of
500 mg/100 ml. Echinacea purpurea extract was kindly
provided by Mepaco-Medifood Co. (Egypt) and was
freshly prepared in distilled water at a concentration of
500 mg/100 ml.
Experimental design
Rats were randomly divided into six groups. Group I
(n = 6) received subcutaneous injections of saline and
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cutaneous injection of isoprenaline (85 mg/kg) for 2
consecutive days at 24-h time intervals for the develop-
ment of infarct-like myocardial lesions [11]. Group III
(n = 12) and V (n = 12) received isoprenaline as in
group II followed by post-treatment daily with oral
doses of Avemar (121 mg/kg) [12] or Echinacea (130
mg/kg) [13], respectively, for 14 days. Group IV ( n =
18) and VI ( n = 18) were pretreated daily with an oral
dose of Avemar (121 mg/kg) or Echinacea (130 mg/kg),
respectively, for 14 days prior to the induction of AMI
and treatment continued for another 14 days after the
development of AMI.
At the end of treatment, animals were anesthetized
with intraperitoneal injection of thiopental (50 mg/kg).
Blood was collected from the retro-orbital sinus at the
following intervals: in the normal group, 1 day after the
last injection; in groups II (AMI group), IV and VI (pre-
and post-treated groups), on days 1, 7 and 14 after in-
duction of myocardial infarction (six animals per time);
in groups III and V (post-treated groups), on days 7 and
14 after induction of myocardial infarction (six animals
per time).
The collected blood was divided into two halves. One
half was used for the separation of serum where aliquots
of the separated serum were stored at −20 °C for subse-
quent determination of creatine kinase (CK), IL-8, GM-
CSF and VEGF. The other half was collected in EDTA-
coated tubes for determination of CD34+ cell counts by
flow cytometry. After blood collection, the animals were
euthanized and the hearts were rapidly excised, washed
with cold saline and kept in formalin for immunohisto-
chemical and histopathological investigations.
Flow cytomytric analysis of CD34+ cells
Flow cytometric analysis of CD34+ cells was performed
at different time intervals immediately after blood collec-
tion. Monoclonal CD34 antibody (10 μl) conjugated to
fluorescein isothiocyanate (Miltenyi Biotec Inc., USA)
was added to 100 μl EDTA blood. The suspension was
incubated for 30 minutes in the dark in the refrigerator
(2–8 °C). VersaLyse lysing solution (1 ml; Immunotech
SAS, France) was added and vortex was carried out im-
mediately for 1 second. The suspension was incubated
for 10 minutes at room temperature protected from
light. Data were acquired using a Beckman Coulter
(Epics XL, Switzerland) flow cytometer. The results are
expressed as a percentage of positive events (CD34+
cells) in relation to all events acquired by gating (10,000
events).
Determination of serum CK activity
Serum CK activity was determined according to the
manufacturer’s instructions given with the CK kit (StanbioLaboratory, USA). This method optimizes the reaction by
reactivation of CK activity with N-acetyl-L-cysteine. The
data was expressed as IU/l.
Determination of serum VEGF, IL-8 and GM-CSF
Serum levels of VEGF, IL-8 and GM-CSF were deter-
mined by a quantitative sandwich enzyme-linked im-
munosorbent assay (ELISA) technique according to the
manufacturer’s instructions. Kits for VEGF and GM-CSF
were obtained from R&D Systems (USA) while that for
IL-8 was obtained from Glory Science Co. (USA). The
concentration of samples was determined from the
standard curves and the results were expressed as pg/ml.
Histological examination
The rat hearts of different groups were isolated 1 day
and 14 days after AMI, washed with ice-cold saline and
fixed in 10 % formol saline for 24 hours. Specimens were
processed for paraffin embedding and 4 μm sections
were prepared. The sections were stained with a
hematoxylin and eosin (H&E) stain and were examined
by the light electric microscope. Histological changes
were evaluated by a pathologist unaware of the type of
treatment. The severity and extent of MI were observed
for each case. The findings were classified into: nil, mild
(focal myocyte damage or small multifocal degeneration
with slight degree of inflammation), moderate (extensive
myofibrillar degeneration and diffused inflammatory re-
action), or severe (necrosis with diffused inflammatory
reaction) [14].
Measurement of capillary density
The effect of Avemar and Echinacea on neovasculariza-
tion was evaluated by counting the number of capillary
vessels within myocardial sections with H&E staining
under light microscopy. A capillary vessel was defined as
a vessel with a diameter less than 200 μm. The number
of capillaries was counted under microscopy (magnifica-
tion ×100) for five random fields in myocardial sections
and presented as mean of blood vessels per unit area
(0.2 mm2). The capillary count of these sections was
compared with the AMI group [15].
Immunohistochemical investigation of CD34+ cells
Immunohistochemical analysis for CD34+ cells was per-
formed 14 days after AMI development on formalin-
fixed, paraffin-embedded cardiac tissue sections using
the NovoLink Polymer Detection System (Leica Micro-
systems, UK) [16]. Endogenous peroxidase activity was
neutralized using the Peroxidase Block. This was
followed by application of the Protein Block to reduce
nonspecific binding of the primary antibody and the
polymer. The sections were subsequently incubated with
diluted rat CD34 antibody (US Biological Co., USA).
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of the subsequent polymer (IgG-Poly-HRP). Peroxidase
activity was developed with 3,3-diaminobenzidine working
solution which produces brown precipitate at the antigen
site. Slides were counterstained with hematoxylin. Exam-
ination was performed using Image Analyzer (Olympus,
USA) where CD34+ cells in the myocardial tissue were
counted in ten fields per slide and the average number of
CD34+ cells was calculated.
Immunohistochemical investigation of α-SMA
Immunohistochemical analysis for alpha-smooth muscle
actin (α-SMA)-positive cells was performed 14 days after
AMI development on formalin-fixed, paraffin-embedded
cardiac tissue sections using a DAKO immunostainer
(DAKO, USA) according to the manufacturer’s protocol.
Sections (4 μm) were deparaffinized and rehydrated
through graded alcohols. Endogenous peroxidase activity
was blocked with 0.3 % hydrogen peroxide for 10 minutes,
and antigens were retrieved for 20 minutes in 10 mmol/l
citrate buffer, pH 6.0, at 98 °C. Nonspecific binding was
blocked with 10 % normal goat serum for 20 minutes.
The tissue slides were incubated with the antibody
(1:500 dilution; DAKO) for 65 minutes at 25 °C. Then
the slides were incubated with a ChemMate DAKO
Envision system (K5007) for 30 minutes at 25 °C and
subsequently reacted with 3,3′-diaminobenzidine as a
chromogen substrate. The nucleus was counterstained
using Mayer hematoxylin. A score from 0 to 3+ was
applied; where 0 = absence of α-SMA positive cells in
5 fields, 1 = 1–5 cells/5 fields, 2 = 6–10 cells/5 fields
and 3 = more than 10 cells/5 fields (magnification
×100).
Statistical analysis
Data are expressed as mean ± standard error. The sig-
nificance of differences between groups was determined
using one-way analysis of variance followed by a post-hoc
procedure (Tukey’s Test). Correlation between variables
was determined using Pearsons correlations. Statistical




AMI 0.28 ± 0.028
AMI post-treated with Avemar 0.28 ± 0.028
AMI pre- and post-treated with Avemar 3.65 ± 0.275ab
AMI post-treated with Echinacea 0.28 ± 0.028
AMI pre- and post-treated with Echinacea 4.22 ± 0.35ab
Data are expressed as mean ± standard error. aSignificantly different from the norm
at P < 0.01. AMI acute myocardial infarction(SPSS®, USA). For all statistical tests, a value of P < 0.05
was considered statistically significant.
Results
Flow cytometric analysis of CD34+ cells
Data given in Table 1 and Fig. 1 show the time course of
circulating CD34+ cells. In the AMI group, these cells
increased on day 7 and peaked on day 14 from the MI
development to fivefold the normal value (P < 0.001).
Pre- and post-treatment with Avemar or Echinacea re-
sulted in a substantial increase in the circulating CD34+
cells in peripheral blood peaking on day 1 after AMI to
about 13- and-15 fold (P < 0. 001), respectively, then
with a decline on day 7 followed by significant increase
on day 14 compared to their corresponding AMI values.
However, post-treatment with Avemar failed to affect
the circulating level of these cells compared to the corre-
sponding AMI group. On the other hand, post-
treatment with Echinacea was more effective; it progres-
sively increased the circulating level of CD34+ cells by
2.3-fold on day 7 followed by 3.2-fold (P < 0.001) on day
14 compared to the corresponding AMI group.
Serum CK activity
Induction of AMI resulted in a fivefold increase (P <
0.001) of serum CK activity 1 day after infarction devel-
opment when compared to the normal group. This ac-
tivity was then comparable to the normal group on days
7 and 14. Post-treatment of AMI rats with Avemar or
Echinacea had no effect on serum CK activity when
compared to their corresponding AMI values. On the
other hand, animals pre- and post-treated with Avemar
or Echinacea showed substantial increases in serum CK
on day 1 after infarction development reaching 243 %
and 247 % (P < 0.001), respectively, of the infarction
values. On continued treatment, the serum CK activities
returned to normal levels after 7 days then increased
again insignificantly with Avemar and significantly with
Echinacea (364 % at P < 0.001) on day 14 after AMI de-
velopment relative to their corresponding infarction
values, as shown in Table 2 and Fig. 2.4+ cells at different time intervals from AMI development
Day 7 Day 14
0.28 ± 0.023
0.91 ± 0.068 1.59 ± 0.14a
0.78 ± 0.07 1.4 ± 0.08a
1.38 ± 0.095a 3.17 ± 0.196ab
2.14 ± 0.09ab 5.1 ± 0.196ab
1.34 ± 0.099a 3.65 ± 0.099ab
al group at P < 0.01. bSignificantly different from the corresponding AMI value
Fig. 1 Flow cytometric plots of peripheral CD34+ cell counts at different time intervals from AMI. a Normal; b AMI group; c AMI post-treated with
Avemar; d AMI pre- and post-treated with Avemar; e AMI post-treated with Echinacea; f AMI pre- and post-treated with Echinacea. d Day
after AMI
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Table 2 Effect of Avemar or Echinacea treatment on serum creatine kinase activity (IU/l) at different time intervals from AMI
development (n = 6/group)
Day 1 Day 7 Day 14
Normal 329 ± 32
AMI 1875 ± 154a 409 ± 45 527 ± 55
AMI post-treated with Avemar 1875 ± 154a 235 ± 19 371 ± 33
AMI pre- and post-treated with Avemar 4566 ± 274ab 219 ± 10 935 ± 83
AMI post-treated with Echinacea 1875 ± 154a 273 ± 25 200 ± 25
AMI pre- and post-treated with Echinacea 4636 ± 144ab 216 ± 16 1922 ± 166ab
Data are expressed as mean ± standard error. aSignificantly different from the normal group at P < 0.01. bSignificantly different from the corresponding AMI value
at P < 0.01. AMI acute myocardial infarction
Abdelmonem et al. Stem Cell Research & Therapy  (2015) 6:172 Page 6 of 17Serum VEGF
Data in Table 3 and Fig. 3 show that rats suffering from
AMI had a progressive increase in VEGF level, reaching
13-fold (P < 0.001) the normal value on day 14 after infarc-
tion development. When AMI rats were post-treated with
Avemar or Echinacea, serum VEGF decreased to one-third
the corresponding AMI values (P < 0.001) on day 14 afterFig. 2 Effect of (a) Avemar treatment or (b) Echinacea treatment on serum
time intervals from the infarction development. Values are expressed as a p
P < 0.05. b Significant difference from the corresponding AMI group at P <
group at P < 0.05infarction development. In groups pre- and post-treated
with Avemar or Echinacea, the VEGF level increased by
4.5-fold (P < 0.001) and by 8.3-fold (P < 0.001) the normal
level, respectively, on day 1 after infarction development.
Moreover, on day 14 these treatments decreased serum
VEGF levels to 33 % and 39 % (P < 0.001), respectively, of
their corresponding AMI values.CK activity in rats with acute myocardial infarction (AMI) at different
ercentage of normal. a Significant difference from the normal group at
0.05. c Significant difference from the corresponding post-treated
Table 3 Effect of Avemar or Echinacea treatment on serum vascular endothelial growth factor level (pg/ml) at different time
intervals from AMI development (n = 6/group)
Day 1 Day 7 Day 14
Normal 26.8 ± 2.1
AMI 53.4 ± 4.7 106.3 ± 10.8a 349.7 ± 33.5a
AMI post-treated with Avemar 53.4 ± 4.7 41.4 ± 4 114.9 ± 9.8ab
AMI pre- and post-treated with Avemar 121.3 ± 8.8a 124.3 ± 7.5a 116.9 ± 11.1ab
AMI post-treated with Echinacea 53.4 ± 4.7 122 ± 12.3a 104 ± 10.9ab
AMI pre- and post-treated with Echinacea 222.5 ± 23.6ab 163.9 ± 12.2a 137.5 ± 14.2ab
Data are expressed as mean ± standard error. aSignificantly different from the normal group at P < 0.05. bSignificantly different from the corresponding AMI value
at P < 0.05. AMI acute myocardial infarction
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Induction of AMI with isoprenaline resulted in an insig-
nificant increase of the serum IL-8 level on day 1 after
AMI development in comparison with the normal
group. Moreover, neither Avemar nor Echinacea treat-
ment could alter the serum IL-8 level significantly com-
pared to their corresponding AMI group (Table 4 and
Fig. 4).Fig. 3 Effect of (a) Avemar treatment or (b) Echinacea treatment on the se
different time intervals from the infarction development. Values are express
group at P < 0.05. b Significant difference from the corresponding AMI con
post-treated group at P < 0.05Serum GM-CSF
Induction of AMI in rats resulted in a progressive de-
crease in serum GM-CSF compared to the normal level
throughout the time course of investigation. Post-
treatment with Avemar did not affect the decrease in the
level of GM-CSF caused by AMI. On the other hand,
post-treatment with Echinacea resulted in more de-
creases in the serum GM-CSF levels on days 7 and 14rum VEGF level in rats with acute myocardial infarction (AMI) at
ed as a percentage of normal. a Significant difference from the normal
trol group at P < 0.05. c Significant difference from the corresponding
Table 4 Effect of Avemar or Echinacea treatment on serum interleukin-8 level (pg/ml) at different time intervals from AMI
development (n = 6/group)
Day 1 Day 7 Day 14
Normal 361 ± 11.7
AMI 448 ± 26.5 371 ± 25.8 314 ± 14.5
AMI post-treated with Avemar 448 ± 26.5 356 ± 31.8 382 ± 31.3
AMI pre- and post-treated with Avemar 438 ± 38.7 413 ± 36.5 411 ± 36.8
AMI post-treated with Echinacea 448 ± 26.5 385 ± 20.2 383 ± 10.4
AMI pre- and post-treated with Echinacea 400 ± 14.8 394 ± 15.9 431 ± 5.5
Data are expressed as mean ± standard error, with no significant difference between groups. AMI acute myocardial infarction
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the normal value. Pre- and post-treatment with Avemar
resulted in more pronounced decreases in serum GM-
CSF to 46 %, 32 % and 36 % (P < 0.001), on days 1, 7
and 14 after AMI development, respectively, compared
to the normal group. However, pre- and post-treatment
with Echinacea did not affect the serum GM-CSF level
on days 1 and 7, but significantly increased its level toFig. 4 Effect of (a) Avemar treatment or (b) Echinacea treatment on the se
time intervals from the infarction development. Values are expressed as a p159 % (P < 0.001) on day 14 compared to their corre-
sponding AMI values (Table 5 and Fig. 5).
Correlation between circulating CD34+ cells and serum CK
activity and cytokines
When the potential relationship between circulating
CD34+ cells and serum CK activity was examined in the
experimental groups (Fig. 6a and b), simple regressionrum IL-8 level in rats with acute myocardial infarction (AMI) at different
ercentage of normal
Table 5 Effect of Avemar or Echinacea treatment on the serum granulocyte macrophage colony-stimulating factor level (pg/ml) at
different time intervals from AMI development (n = 6/group)
Day 1 Day 7 Day 14
Normal 23.45 ± 1.97
AMI 18.68 ± 1.63 16.2 ± 1.37a 13.58 ± 0.87a
AMI post-treated with Avemar 18.68 ± 1.63 13.5 ± 1.2a 13.02 ± 3.66a
AMI pre- and post-treated with Avemar 10.8 ± 1.06ab 7.4 ± 0.35ab 8.48 ± 0.58a
AMI post-treated with Echinacea 18.68 ± 1.63 7.13 ± 0.78ab 7.77 ± 0.59ab
AMI pre- and post-treated with Echinacea 18.89 ± 1.36 15.38 ± 1.07a 21.66 ± 1.6b
Data are expressed as mean ± standard error. aSignificantly different from the normal group at P < 0.05. bSignificantly different from the corresponding AMI value
at P < 0.05. AMI acute myocardial infarction
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counts and serum CK activity in groups treated with
Avemar or Echinacea (r = 0.732 and 0.373, respectively;
P < 0.05). Moreover, a positive correlation was also
found between the serum level of VEGF and circulating
CD34+ in Avemar-treated groups (r = 0.448; P < 0.05;
Fig. 6c). No significant relationship was found betweenFig. 5 Effect of (a) Avemar treatment or (b) Echinacea treatment on serum
intervals from the infarction development. Values are expressed as a percen
P < 0.05. b Significant difference from the corresponding AMI control group a
group at P < 0.05these cells and other cytokines in the Avemar- or
Echinacea-treated groups.
Immunohistochemical investigation of CD34+ cells
The AMI group did not show any significant change in
the number of CD34+ cells in myocardial tissue on day
14 when compared to the normal group (Figs. 7 and 8).GM-CSF in rats with acure myocardial infarction (AMI) at different time
tage of normal. a Significant difference from the normal group at
t P < 0.05. c Significant difference from the corresponding post-treated
Fig. 6 Correlation between circulating CD34+ cells and serum CK activity or serum VEGF level. a Correlation between circulating CD34+ cells and
serum creatine kinase (CK) activity in Avemar-treated groups. b Correlation between circulating CD34+ cells and serum CK activity in Echinacea-treated
groups. c Correlation between circulating CD34+ cells and serum vascular endothelial growth factor (VEGF) in Avemar-treated groups. Values of
P < 0.05 are considered statistically significant: * significant at P < 0.05. ** significant at P < 0.01
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in the number of CD34+ cells in myocardial tissue. On
the other hand, pre- and post-treatment with Avemar
caused a greater significant increase in CD34+ cell homing
by 268 % (P < 0.001) on day 14 after infarction develop-
ment than in the AMI group. Post-treatment with Echin-
acea increased CD34+ cell homing to 221 % (P < 0.001)
and its pre- and post-treatment resulted in more homingat the myocardium reaching to267% (P < 0.001) of their
AMI group.
Immunohistochemical investigation of α-SMA-positive cells
Positive staining for α-SMA was present only in the wall
of coronary vessels of the control group. In the AMI
group, few cells showing positive staining for α-SMA
were recognized. On the other hand, homing of CD34+
Fig. 7 Immunohistochemical analysis for CD 34+ cells 14 days after infarction development. a Normal; b AMI group; c AMI post-treated with
Avemar; d AMI pre- and post-treated with Avemar; e AMI post-treated with Echinacea; f AMI pre- and post-treated with Echinacea. Magnification ×400
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accompanied by higher expression of α-SMA 14 days
after infarction. α-SMA-positive cells were increased in
Avemar-treated groups with both vascular and separate
scattered myofibroblast-like cells. In Echinacea pre- and
post-treated rats, especially after 14 days of infarction, α-
SMA-positive cells mostly gained histological features
characteristic of pericytes in the wall of newly formed
capillaries (Table 6 and Fig. 9).
Histopathology
Histopathological analysis of the AMI group revealed
a severe inflammatory reaction on day 1 after infarction
development. This was represented by cardiac muscular
degeneration, inflammatory cell infiltration, edema
and hyalinization. Fourteen days after infarction, theinflammatory reaction was moderate and the natural
healing process had started. Treatment with Avemar
after infarction development resulted in a better heal-
ing of the myocardial tissue. In rats pre- and post-
treated with Avemar, there was still a severe inflam-
matory reaction on day 1 after induction of AMI
which disappeared after 14 days. The inflammation
also disappeared in the group post-treated with Echin-
acea 14 days after AMI. In rats pre- and post-treated
with Echinacea, there was a mild inflammatory reac-
tion on days 1 and 14 after infarction development
(Fig. 10).
Capillary density
Regarding capillary density as index of neovasculariza-
tion, H&E staining showed marked augmentation of
Fig. 8 Average numbers of CD34+ cells in myocardial tissue 14 days after acute myocardial infarction (AMI) development. a Significant difference
from the normal group at P < 0.05. b Significant difference from the AMI group at P < 0.05
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groups. Semiquantitative analysis showed significant in-
creases in newly formed capillaries in treated groups
compared to the AMI group 14 days after infarction,
with more remarkable values detected in the Echinacea
post-treated and pre- and post-treated groups compared
to other groups (Fig. 11).Discussion
In MI, stimulation of endogenous SC potential helps in
healing and regeneration of damaged myocardial tissue
[3]. A tissue regeneration approach that relies on en-
dogenous SC mobilization and homing would be less
costly and less complex than approaches that require sub-
stantial ex-vivo cell manipulation and use of artificial vehi-
cles for cell delivery [2]. Dietary strategies for supporting
SC biology represent an emerging field of nutritional
medicine. The current study is the first one that investi-
gates the possible beneficial role of two natural products,
namely Avemar and Echinacea, on SC mobilization and
homing, as well as their modulatory role on damaged
myocardial tissue in relation to cytokines.Table 6 Effect of Avemar or Echinacea treatment on
α-SMA-positive cells 14 days after infarction development
Score of α-SMA-positive cells
Post-treatment with Avemar +3
Pre- and post-treatment with avemar +2
Post-treatment with Echinacea +2
Pre- and post-treatment with Echinacea +1
A score from 0 to 3+ was applied, where 0 = absence of alpha-smooth muscle
actin (α-SMA)-positive cells in 5 fields, 1 = 1–5 cells/5 fields, 2 = 6–10 cells/5
fields and 3 = more than 10 cells/5 fieldsIn this study, induction of AMI using isoprenaline re-
sulted in increased circulating CD34+ cells with a peak
on day 14 from infarction development. This finding is
supported by previous studies in both animal models
[17] and AMI patients [18]. The major problem of these
mobilized CD34+ cells which limits their ability to re-
generate the damaged myocardial tissue is their relatively
low count in the circulation. Therefore, there is a great
need for the discovery of new agents that induce
mobilization of more SCs from their resident niches into
the systemic circulation.
The data from the current study revealed that treat-
ment with Avemar or Echinacea pre- and post-infarction
efficiently induced great mobilization of CD34+ cells
from their niches on day 1 and 14 after AMI. On the
other hand, animals that received Avemar only after
infarction development exhibited no change in the
mobilization of SCs, while those receiving Echinacea
showed more circulating CD34+ cells on days 7 and 14
compared to their corresponding AMI values. These re-
sults revealed the importance of Avemar as a prophylac-
tic agent and Echinacea as both a prophylactic and
therapeutic agent triggering an efficient mobilization of
CD34+ cells which may, in turn, contribute to regener-
ation of damaged myocardium. Increased SC mobilization
could be explained according to the established concept
that, within the BM, SCs are anchored to stromal cells
via integrin binding to cell adhesion molecules and via
interaction with cell surface- or matrix-bound cytokines
[19]. Disruption of this interaction represents the prin-
cipal underlying mechanism of several currently applied
mobilization strategies including colony-stimulating factors
such as G-CSF and GM-CSF. Another underlying mech-
anism depends on increasing serum levels of growth
Fig. 9 Immunohistochemical investigation of α-SMA positive cells 14 days after infarction development. a Normal; b AMI group; c AMI post-treated
with Avemar; d AMI pre- and post-treated with Avemar; e AMI post-treated with Echinacea; f AMI pre- and post-treated with Echinacea.
Magnification ×400
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the blood, such as VEGF, erythropoietin, and IL-8 [3, 20].
The circulating levels of SCs in case of pre- and post-
treatment with Avemar or Echinacea decreased to a cer-
tain extent after 7 days and then increased significantly
again after 14 days, suggesting a migration of CD34+ cells
to the infarcted myocardium.
Induction of AMI resulted in increased serum CK activ-
ity on day 1 after infarction suggesting a loss of cellular
membrane integrity with myocardial cell damage [21, 22].
Importantly, our study demonstrated that intake of Echin-
acea or Avemar for 14 days before the development of MI
significantly increased CK activity on day 1 after MI when
compared to the untreated group. This increase may be
explained in the light of SC-based cardiogenesis. SCdifferentiation is an energy-dependent process which re-
quires constant metabolic signaling between the cytosol
and nucleus to control gene expression. In particular, SC
cardiogenesis involves robust electrical and functional ac-
tivities that require additional energy requirements and
coordinated signal communication [23]. CK isoforms are
the major phosphotransfer circuit in adult cardiomyocytes
which connects mitochondrial energetics with ATP-
consuming processes in the nucleus and myofibrils [24].
Thus, cardiomyocyte differentiation is accompanied by
enhancement of CK circuits and total activity to meet in-
creased demands for energetic communication. In har-
mony with this theory, Chung and colleagues previously
reported that treatment of differentiating SCs with bone
morphogenetic protein 2, a cardiogenic growth factor,
Fig. 10 Histopathological analysis of myocardial tissue after AMI development (stained by H&E stain). a Normal; b AMI group; c AMI post-treated
with Avemar; d AMI pre- and post-treated with Avemar; e AMI post-treated with Echinacea; f AMI pre- and post-treated with Echinacea. d Days
after AMI; h hyalinization, m inflammatory cells infiltration, o edema, v newly formed blood capillaries
Fig. 11 Effect of Avemar and Echinacea treatments on capillary density in the myocardium 14 days after acute myocardial infarction (AMI)
development (mean ± standard error). a Significant difference from AMI group at P < 0.05
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positive correlation between the circulating CD34+ cells
and serum CK activity was observed in groups treated
with Avemar or Echinacea.
Generally speaking, SC mobilization from the BM and
other tissue niches into the circulation is guided by the
interplay of several molecular and cellular mechanisms
[3]. In the present study, a significant increase in serum
VEGF was observed on day 7 after MI. In agreement
with this result, a high serum VEGF level was previously
found in clinical [25] and experimental [26] AMI. The
elevated VEGF level at the acute phase of MI may be
triggered through the activation of hypoxia-inducible
factor-1 and/or it may be an adaptive mechanism for in-
ducing neovascularization in ischemic myocardium [27].
In groups pre- and post-treated with Avemar or Echin-
acea, higher increases in serum VEGF were shown com-
pared to the untreated group on day 1 after infarction
development. Such increases might be responsible for
the elevation in circulating CD34+ cells. Previous studies
pointed to a positive correlation between plasma VEGF
and the number of CD34+ cells in MI patients [28, 29].
Additionally, VEGF may also enhance the adhesive po-
tential of progenitor cells within the myocardium, their
homing capacity and subsequently their potential regen-
erative ability [29]. In spite of these previously men-
tioned beneficial roles, there is evidence that elevated
levels of endogenous VEGF are associated with an in-
flammatory reaction in patients with acute coronary syn-
drome [27]. Likewise, atorvastatin treatment after MI
resulted in a decline in the level of VEGF which was cor-
related with improvement of post-MI ventricular dys-
function and may account for the clinical benefit in the
chronic phase of MI [27]. In the current study, the early
increases in the VEGF level in groups pre- and post-
treated with Avemar or Echinacea were followed by sig-
nificant decreases on day 14; such effects may represent
additional benefits of Avemar or Echinacea for AMI
patients.
With regard to IL-8, our results showed insignificant
increases of serum IL-8 level on day 1 after the last iso-
prenaline dose. Schömig and colleagues previously dem-
onstrated an elevation of plasma IL-8 level in patients
with AMI together with enhanced CD133 progenitor cell
mobilization [30]. However, in the current study, the in-
significant increases in plasma IL-8 could be attributed
to the relatively short half-life of IL-8 (8 minutes in non-
human primates) [31]. Moreover, neither Avemar nor
Echinacea treatment could change serum IL-8 levels
when compared to the AMI group. On the contrary,
Kapai and colleagues reported that Echinacea purpurea
preparations have a stimulatory effect on the production
of IL-8 by mononuclear leukocytes in vitro [9]. Add-
itionally, Ernesto and colleagues found substantialdifferences in the gene expression of IL-8 according to
the type of Echinacea preparation [32].
In the current study, induction of AMI resulted in a
progressive reduction of serum GM-CSF reaching the
lowest level on day 14 of MI. Such a reduction in GM-
CSF might be attributed to its uptake by polymorpho-
nuclear cells (PMNs). In response to MI injury, mature
PMNs in the BM are recruited to the myocardium where
their chemoattraction is regulated by several chemokines
and cytokines [33, 34]. These PMNs are able to clear up
GM-CSF from the circulation [35]. Also, an increased
circulating level of GM-CSF is a basal part of the persist-
ent inflammatory reaction during cardiac repair which
may augment cardiac dysfunction through the increased
oxidative stress and the enhanced cardiomyocyte apop-
tosis and extracellular matrix degradation [36]. There-
fore, continued reduction of serum GM-CSF levels by
treatment with Avemar or by post-treatment with Echin-
acea is assumed to be beneficial in preventing left ven-
tricular remodeling. Moreover, the lowered serum GM-
CSF by Avemar treatment or by post-treatment with
Echinacea is assumed to provide a chance for more
CD34+ cells to differentiate into cardiomyocytes or
endothelial cells rather than into granulocytes or macro-
phages. On the other hand, in groups pre- and post-
treated with Echinacea, the GM-CSF level was increased
on day 14 which might be attributed to the immune en-
hancing properties of Echinacea. GM-CSF transcription
was reported to be downregulated by the rhinovirus and
upregulated to some extent by treatment with Echinacea
which supports this assumption [37]. These differences
in serum GM-CSF levels between Echinacea-treated
groups may account for the histopathological findings
where the group post-treated with Echinacea showed no
inflammatory reaction while the pre- and post-treated
group showed a mild inflammatory reaction.
Immunohistochemical data in the current study re-
vealed successful recruitment and homing of the mobi-
lized CD34+ cells to the damaged myocardium in the
case of post- treatment with Echinacea and pre- and
post-treatment with Avemar or Echinacea. The claimed
participation of these recruited CD34+ cells in myocar-
dial regeneration after AMI in response to the above
treatment may involve either direct incorporation of
these cells into the newly developing vasculature and/or
the production and secretion of angiogenic cytokines
[38, 39]. Parallel to this finding, α-SMA-positive cells
were increased in Avemar-treated groups with both vas-
cular and separate scattered myofibroblast-like cells.
Likewise, in Echinacea-treated groups, α-SMA-positive
cells mostly gained histological features characteristic of
pericytes in the wall of newly formed capillaries. In
addition, a predominant presence of CD34+ cells in the
endothelium of several vessels suggested their
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contribute to the significantly higher capillary density in
the treated groups, particularly in Echinacea groups.
Therefore, the overall increase in capillary density and
transdifferentiation into vascular smooth muscle cells
seen in the treated groups may ultimately help in regen-
eration of damaged myocardium. It was reported that
endothelial progenitor cells derived from CD34+ cells
could differentiate to endothelial- and smooth muscle-
like cells and contribute to the development of coopera-
tive vascular networks [40]. The possible mechanism of
Avemar and Echinacea in recruitment and homing of
SCs may depend on their antioxidant properties. The ex-
tracts of all Echinacea species and likewise Avemar con-
tain several polyphenolic compounds and large amounts
of flavonoids, having a potent antioxidant activity [41,
42]. Antioxidants have also been shown to play a major
role in the regenerative potential of muscle-derived SCs
in skeletal and cardiac muscles [43], as well as in enhan-
cing the proliferation of adipose-derived mesenchymal
SCs in vitro [44]. Other unknown mechanisms are not
ruled out and need further research.
Histopathological changes in the heart from AMI ani-
mals might be attributed partially to the state of oxida-
tive stress following isoprenaline injection which directly
harms the cardiomyocytes and endothelial cells [45].
Treatment with Avemar or Echinacea resulted in re-
duced inflammatory reactions in the myocardial tissues
which could be explained in the case of Avemar by its
anti-inflammatory effect through the inhibition of the
cyclooxygenases [46], while in Echinacea it could be at-
tributed to the inhibition of free radical production in
the development of inflammation [47]. Such a reduction
in inflammatory reactions by Avemar and/or the inhib-
ition of free radical production by Echinacea may help
in creating a supportive environment for the homing
SCs at the myocardium to promote their survival and ul-
timately may enhance their regenerative potentials.
Conclusion
In conclusion, for the first time, we showed that admin-
istration of Avemar and Echinacea extracts effectively
triggered the mobilization and homing of CD34+ stem
cells to the infarcted myocardium and thus may enhance
SC-based regeneration of the myocardial tissue. The po-
tential of these safe and cheap products as additional
therapeutic agents holds great promise for MI. Mecha-
nisms of SC mobilization by these products needs to be
unraveled.
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